Adiponectin in Obese Women With T2DN and Effects by RAS Blocker
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00561704 |
Recruitment Status
:
Completed
First Posted
: November 21, 2007
Last Update Posted
: November 21, 2007
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Obese Type 2 Diabetes Diabetic Nephropathy Glucose Metabolism Angiotensin II Type 1 Receptor Blockers | Drug: losartan | Not Applicable |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 80 participants |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Adiponectin in Obese Women With T2DN and Effects by RAS Blocker |
Study Start Date : | April 2007 |
Actual Study Completion Date : | October 2007 |

-
Drug: losartan
- GFR, HbA1c and the adiponectin concentration. [ Time Frame: 6 month ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 30 Years and older (Adult, Senior) |
Sexes Eligible for Study: | Female |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Type 2 diabetic nephropathy
- CKD at stage 1~4
Exclusion Criteria:
- Type 1 diabetes or nondiabetic renal disease
- An elevated plasma K level.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00561704
Principal Investigator: | hui min Jin, MD | shanghai No 3 people's hospital |
ClinicalTrials.gov Identifier: | NCT00561704 History of Changes |
Other Study ID Numbers: |
ADL |
First Posted: | November 21, 2007 Key Record Dates |
Last Update Posted: | November 21, 2007 |
Last Verified: | November 2007 |
Keywords provided by Shanghai Jiao Tong University School of Medicine:
obese female Type 2 Diabetes Diabetic Nephropathy |
Glucose Metabolism Angiotensin II Type 1 Receptor Blockers Adiponectin |
Additional relevant MeSH terms:
Diabetes Mellitus, Type 2 Kidney Diseases Diabetic Nephropathies Diabetes Mellitus Glucose Metabolism Disorders Metabolic Diseases Endocrine System Diseases Urologic Diseases |
Diabetes Complications Losartan Angiotensin II Type 1 Receptor Blockers Anti-Arrhythmia Agents Antihypertensive Agents Angiotensin Receptor Antagonists Molecular Mechanisms of Pharmacological Action |